Q-omics provides the consensus-scored MIR3690 profile across patient tissues and cancer cell-line models. MIR3690 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR3690 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MIR3690 RNA expression shows 8,256 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight CESC, KIRC, and BRCA as cancer lineages where MIR3690 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3690 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3690 survival associations across molecular data types. MIR3690 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3690 RNA expression–survival associations across cancer types. High MIR3690 expression shows unfavorable associations in LIHC, THCA, UVM, BRCA and LGG, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify CESC as the clearest survival context for MIR3690 RNA expression.
This table summarizes MIR3690 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3690. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3690 shows lower tumor expression in BRCA and higher tumor expression in KIRC, STAD and PAAD. The KIRC box plot shows higher MIR3690 RNA expression in tumor versus normal tissue (log2 FC = +0.216, t-test p < 0.001).
This table shows molecular features associated with MIR3690 in patient tissues and cancer cell lines. In patient samples, MIR3690 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
